Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:03 AM ET

Sponsor Check › Person

No photo found yet (own website and image search run after this page is viewed)

Guy Regev

Named as an officer, director or promoter on SEC Form D filings · Israel (as filed: L3) · Mar 24, 2014 → Sep 10, 2026

1deal (issuers)

$10Mreported sold

16investors

15Form D filings

2014–2026years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:30 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Guy Regev is listed as a director on 15 SEC Form D filings by 1 issuer between Mar 2014 and Sep 2026: Can-Fite BioPharma Ltd. (Ramat Gan, Israel (as filed: L3) — pharmaceuticals — 2014–2026; $10M reported sold to 16 investors).

What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.

Listed alongside Motti Farbstein (15 shared filings), Pnina Fishman (15 shared filings), Ilan Cohn (14 shared filings), Israel Shamay (10 shared filings), Abraham Sartini (9 shared filings) and 11 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Guy. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 court cases matching the name, 2 bankruptcy cases matching the name listed in Key records below.

What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 15 public filings for Guy Regev and found 2 differences: Address moved from Petach Tikva, Israel (as filed: L3) to Ramat Gan, Israel (as filed: L3); Reported revenue range changed between filings.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Guy Regev has not run yet — it is joining a line of 5,441 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

3 cases: 1 closed (disposition not in docket feed), 1 dismissed, 1 judgment

Regev Investments v. Hicks closed

District Court, N.D. Georgia · No. 1:17-cv-04293 · Filed Oct 27, 2017 · Closed Nov 1, 2017 · Nature of suit: 230 Rent, lease, ejectment

Role of Regev Investments: Plaintiff · Outcome: Terminated 2017-11-01 — FJC Integrated Database disposition: Remanded to state court Docket on CourtListener ↗

same rare surname (4 people in Form D filings, 5 federal dockets); surname only in the caption; court in GA (not a filing state)

Merrick Park LLC v. Regev dismissed

District Court, S.D. New York · No. 1:04-cv-05031 · Filed Jun 25, 2004 · Closed Aug 25, 2004 · Nature of suit: 190 Other contract actions

Role of Regev: Defendant · Outcome: Terminated 2004-08-25 — FJC Integrated Database disposition: Dismissed: other Docket on CourtListener ↗

same rare surname (4 people in Form D filings, 5 federal dockets); surname only in the caption; court in NY (not a filing state)

Boardwalk Reg. Corp. v. Regev judgment

District Court, S.D. New York · No. 1:95-cv-00500 · Filed Jan 23, 1995 · Closed Apr 11, 1995 · Nature of suit: 140 Negotiable instruments

Role of Regev: Defendant · Outcome: Terminated 1995-04-11 — FJC Integrated Database disposition: Judgment on default; judgment for plaintiff Docket on CourtListener ↗

same rare surname (4 people in Form D filings, 5 federal dockets); surname only in the caption; court in NY (not a filing state)

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:30 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Guy Regev..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

2 cases: 2 closed (disposition not in docket feed)

O.H.Y. Regev Remodeling, Inc. closed

United States Bankruptcy Court, N.D. Georgia · No. 15-70259 · Filed Oct 21, 2015 · Closed Dec 21, 2018

Role of O.H.Y. Regev Remodeling, Inc.: Debtor · Outcome: Case closed 2018-12-21 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same rare surname (4 people in Form D filings, 5 federal dockets); surname only in the caption; court in GA (not a filing state)

Sterling National Bank v. Regev closed

United States Bankruptcy Court, S.D. New York · No. 05-02368 · Filed Aug 5, 2005 · Closed Nov 1, 2005

Role of Regev: Defendant · Outcome: Case closed 2005-11-01 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same rare surname (4 people in Form D filings, 5 federal dockets); surname only in the caption; court in NY (not a filing state)

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:30 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

2 differences found between the filings for Guy Regev (compared 15 filings on Oct 24, 2026)

Note · Dec 30, 2021 – Sep 10, 2026

Address moved from Petach Tikva, Israel (as filed: L3) to Ramat Gan, Israel (as filed: L3) — Can-Fite BioPharma Ltd.

The people listed on the Dec 30, 2021 filing give Petach Tikva, Israel (as filed: L3); on the Sep 10, 2026 filing they give Ramat Gan, Israel (as filed: L3).

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Dec 30, 2021 ↗Form D · Sep 10, 2026 ↗Can-Fite BioPharma Ltd. — PartnerFacts page ↗

Sources

Form D · Dec 30, 2021 ↗ (Dec 30, 2021)
Form D · Sep 10, 2026 ↗ (Sep 10, 2026)
Can-Fite BioPharma Ltd. — PartnerFacts page ↗ (Sep 10, 2026)

Note · Mar 24, 2014 – Oct 2, 2015

Reported revenue range changed between filings — Can-Fite BioPharma Ltd.

"No Revenues" (Mar 24, 2014); then "Decline to Disclose" (Oct 2, 2015).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Mar 24, 2014 ↗Form D · Oct 2, 2015 ↗Can-Fite BioPharma Ltd. — PartnerFacts page ↗

Sources

Form D · Mar 24, 2014 ↗ (Mar 24, 2014)
Form D · Oct 2, 2015 ↗ (Oct 2, 2015)
Can-Fite BioPharma Ltd. — PartnerFacts page ↗ (Sep 10, 2026)

What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

15 of 15 offerings report sales commissions totalling $5,609,368; 0 report finder's fees; 0 report proceeds to related persons.

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Sep 10, 2026 D Can-Fite BioPharma Ltd. File 021-597072	$278,554	$0	$0 Issuer expects to use any proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.. No proceeds are expected to be paid to executive officers, directors, or promoters.	H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗	EDGAR ↗
Dec 30, 2021 D Can-Fite BioPharma Ltd. File 021-427466	$700,000	$0	$0 Issuer expects to use proceeds from the offering for working capital which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Aug 26, 2021 D Can-Fite BioPharma Ltd. File 021-411441	$700,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Jul 17, 2020 D Can-Fite BioPharma Ltd. File 021-371320	$255,825	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Jun 19, 2020 D Can-Fite BioPharma Ltd. File 021-369370	$600,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Jan 24, 2020 D Can-Fite BioPharma Ltd. File 021-358933	$168,945	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
May 31, 2019 D Can-Fite BioPharma Ltd. File 021-340869	$360,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Apr 11, 2019 D Can-Fite BioPharma Ltd. File 021-337116	$192,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Jan 24, 2019 D Can-Fite BioPharma Ltd. File 021-331328	$141,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Mar 22, 2018 D Can-Fite BioPharma Ltd. File 021-308386	$300,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Jan 25, 2017 D Can-Fite BioPharma Ltd. File 021-279241	$300,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Oct 28, 2015 D Can-Fite BioPharma Ltd. File 021-250254	$289,500	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Oct 2, 2015 D Can-Fite BioPharma Ltd. File 021-248685	$540,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Dec 17, 2014 D Can-Fite BioPharma Ltd. File 021-230290	$480,000	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗ ROTH Capital Partners, LLC BrokerCheck CRD 15407 ↗	EDGAR ↗
Mar 24, 2014 D Can-Fite BioPharma Ltd. File 021-214130	$303,544	$0	$0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers	ROTH Capital Partners, LLC BrokerCheck CRD 15407 ↗	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 1

Every issuer that named Guy Regev on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Pharmaceuticals

Can-Fite BioPharma Ltd.

Ramat Gan, Israel (as filed: L3) · Mar 24, 2014 → Sep 10, 2026 · 15 filings

Sep 10, 2026 · D · $8,306,884 sold of $8,306,884 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 30, 2021 · D · $10,000,000 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Aug 26, 2021 · D · $9,996,900 sold of $9,996,900 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 17, 2020 · D · $3,411,000 sold of $3,411,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 19, 2020 · D · $8,000,002 sold of $8,000,002 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 24, 2020 · D · $2,400,000 sold of $2,400,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
May 31, 2019 · D · $6,000,000 sold of $6,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
Apr 11, 2019 · D · $3,200,000 sold of $3,200,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 24, 2019 · D · $2,350,000 sold of $2,350,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 22, 2018 · D · $5,000,004 sold of $5,000,004 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 25, 2017 · D · $5,000,000 sold of $5,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 28, 2015 · D · $4,825,002 sold of $4,825,002 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 2, 2015 · D · $9,000,002 sold of $9,000,002 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 17, 2014 · D · $8,000,000 sold of $8,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 24, 2014 · D · $5,059,072 sold of $5,059,072 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10M from 16 investors (100% of the $8.31M target) as of the latest filing. Guy is listed as director on 15 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

People around Guy 16

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

No photo found yet (own website and image search run after this page is viewed)

Person

Pnina Fishman

Executive Officer, Director · 15 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Motti Farbstein

Executive Officer, Director · 15 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Ilan Cohn

Director · 14 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Israel Shamay

Director · 10 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Yaacov Goldman

Director · 9 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Abraham Sartini

Director · 9 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Abraham Sartani

Director · 6 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Gil Oren

Director · 5 shared filings (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Yechezkel Barenholz

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Barak Singer

Director · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Yoseph Bornstein

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Golan Bitton

Director · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Yoseph Borenstein

Director · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Yossi Bornstein

Director · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Sari Fishman

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

No photo found yet (own website and image search run after this page is viewed)

Person

Ilan Tamir

Director · 1 shared filing (1 issuer)

Listed on the same filings as Guy Regev. Their page shows their other deals.

Registrations and other filings

Adviser registration (Form ADV)

None of the 1 issuer this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Guy Regev by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 1 issuer this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Guy Regev is listed on: none on file. No website or social profile named in Can-Fite BioPharma Ltd.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #9,443 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Ramat Gan, L3). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Guy Regev appears on a new Form D, or when a court case or SEC action is matched to them. See plans →

Guy Regev

The short version

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

Address moved from Petach Tikva, Israel (as filed: L3) to Ramat Gan, Israel (as filed: L3) — Can-Fite BioPharma Ltd.

Reported revenue range changed between filings — Can-Fite BioPharma Ltd.

5. Money to insiders

Deals 1

People around Guy 16

Registrations and other filings

Adviser registration (Form ADV)

Other offering types (Regulation A and Regulation Crowdfunding)

Public profiles and social

Look further

Social and web

Courts

Securities regulators

Business registries

Change history

Request a correction

Add a response

Monitor this person